New immunotherapy company joining Peregrine's cancer-related companies portfolio.
Ribon Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.
Ribon Therapeutics is exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. The company is building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas.
Ribon’s lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer.
